Core Viewpoint - The stock price of Gilead Sciences-B (01672) has increased over 3%, with a cumulative rise of over 100% in the past month, reflecting strong market performance and positive developments in its drug pipeline [1] Financial Performance - For the six months ending June 30, 2025, the company reported total revenue of RMB 104 million, representing a year-on-year increase of 111.4% [1] - Research and development costs amounted to RMB 147 million, showing a year-on-year increase of 10.9% [1] - The loss attributable to equity shareholders was RMB 87.95 million, a reduction of 32.5% compared to the previous year [1] - The loss per share was reported at 9.14 cents [1] Drug Development Progress - Significant advancements were made in the metabolic disease pipeline, immune disease pipeline, and expanded indication product pipeline [1] - The ASC30 oral tablet for obesity treatment demonstrated a weight reduction of up to 6.5% after 28 days in a U.S. Phase Ib study, indicating its potential as a best-in-class candidate for obesity treatment [1] - The company initiated a U.S. Phase IIa study and rapidly enrolled 125 participants within just over a month [1] - The ASC30 subcutaneous injection, administered once monthly or less frequently, showed a half-life of 36 days in obesity patients during a U.S. Phase Ib study, supporting its potential for less frequent dosing [1]
歌礼制药-B涨超3% 中期股东应占亏损同比收窄32.5% ASC30美国Ib期研究数据向好